



Clinical trial results:

A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose Inhaled Corticosteroid Therapy

Summary

EudraCT number	2007-004459-13
Trial protocol	PL EE GR SK DE
Global end of trial date	24 November 2008

Results information

Result version number	v1 (current)
This version publication date	13 April 2016
First version publication date	06 March 2015

Trial information

Trial identification

Sponsor protocol code	FFA109685
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000431-PIP08-07
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 January 2009
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	24 November 2008
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The objective of this study was to evaluate the dose response, efficacy and safety of four dosage regimens of GW685698X (100 µg, 200 µg, 300 µg and 400 µg) administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent uncontrolled asthma.

Protection of trial subjects:

Subjects had to meet all inclusion and none of the exclusion criteria at screening and at end of run-in period to be eligible for randomization to treatment period. During the study, subjects monitored their lung function and recorded asthma symptoms and use of rescue-medication twice daily on an electronic diary. Alert messages to contact the site were programmed should the subject's asthma deteriorate according to pre-defined criteria. Adverse events were captured at each clinic visit.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 December 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 21
Country: Number of subjects enrolled	Slovakia: 18
Country: Number of subjects enrolled	Estonia: 32
Country: Number of subjects enrolled	Germany: 75
Country: Number of subjects enrolled	Greece: 62
Country: Number of subjects enrolled	Canada: 49
Country: Number of subjects enrolled	Korea, Republic of: 132
Country: Number of subjects enrolled	Mexico: 107
Country: Number of subjects enrolled	Philippines: 231
Country: Number of subjects enrolled	Romania: 29
Country: Number of subjects enrolled	Russian Federation: 58
Country: Number of subjects enrolled	South Africa: 56
Country: Number of subjects enrolled	United States: 536
Worldwide total number of subjects	1406
EEA total number of subjects	237

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	191
Adults (18-64 years)	1125
From 65 to 84 years	90
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Participants (par.) meeting eligibility criteria at the Screening visit completed a 28-day Run-in Period for Baseline safety evaluations and measures of asthma status. Par. were then randomized to an 8-week Treatment Period. 1406 par. were screened, and 622 par. were randomized, out of which 615 par. received at least one dose of study treatment.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Local use

Dosage and administration details:

Twice daily dry powder inhaler

Arm title	GW685698X 100 µg OD
------------------	---------------------

Arm description:

Participants received GW685698X 100 micrograms (µg) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Arm type	Experimental
Investigational medicinal product name	GW685698X
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Local use

Dosage and administration details:

100 µg once daily, dry powder inhaler

Arm title	GW685698X 200 µg OD
------------------	---------------------

Arm description:

Participants received GW685698X 200 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Arm type	Experimental
Investigational medicinal product name	GW685698X
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Local use

Dosage and administration details:

200 µg once daily, dry powder inhaler

Arm title	GW685698X 300 µg OD
------------------	---------------------

Arm description:

Participants received GW685698X 300 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Arm type	Experimental
Investigational medicinal product name	GW685698X
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Local use

Dosage and administration details:

300 µg once daily, dry powder inhaler

Arm title	GW685698X 400 µg OD
------------------	---------------------

Arm description:

Participants received GW685698X 400 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Arm type	Experimental
Investigational medicinal product name	GW685698X
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Local use

Dosage and administration details:

400 µg once daily, dry powder inhaler

Arm title	FP 250 µg BID
------------------	---------------

Arm description:

Participants received fluticasone propionate (FP) 250 µg BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Arm type	Active comparator
Investigational medicinal product name	FP
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Local use

Dosage and administration details:

250 µg twice daily, dry powder inhaler

Number of subjects in period 1^[1]	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD
Started	107	105	101
Completed	66	88	87
Not completed	41	17	14
Consent withdrawn by subject	2	3	1
Physician decision	-	1	-
Adverse event, non-fatal	-	3	1
Lost to follow-up	1	-	-
Lack of efficacy	35	10	11
Protocol deviation	3	-	1

Number of subjects in period 1^[1]	GW685698X 300 µg OD	GW685698X 400 µg OD	FP 250 µg BID
Started	103	99	100
Completed	92	86	81
Not completed	11	13	19
Consent withdrawn by subject	2	1	2
Physician decision	-	2	1
Adverse event, non-fatal	-	2	1
Lost to follow-up	-	1	-
Lack of efficacy	8	7	14
Protocol deviation	1	-	1

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Participants (par.) meeting eligibility criteria at the Screening visit completed a 28-day Run-in Period for Baseline safety evaluations and measures of asthma status. Par. were then randomized to an 8-week Treatment Period. 1406 par. were screened, and 622 par. were randomized, out of which 615 par. received at least one dose of study treatment.

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study.	
Reporting group title	GW685698X 100 µg OD
Reporting group description: Participants received GW685698X 100 micrograms (µg) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	
Reporting group title	GW685698X 200 µg OD
Reporting group description: Participants received GW685698X 200 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	
Reporting group title	GW685698X 300 µg OD
Reporting group description: Participants received GW685698X 300 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	
Reporting group title	GW685698X 400 µg OD
Reporting group description: Participants received GW685698X 400 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	
Reporting group title	FP 250 µg BID
Reporting group description: Participants received fluticasone propionate (FP) 250 µg BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	

Reporting group values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD
Number of subjects	107	105	101
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	39.1 ± 16.19	38.3 ± 16.76	38.8 ± 15.97
Gender categorical Units: Subjects			
Female	74	72	63
Male	33	33	38

Race, Customized Units: Subjects			
White	62	64	65
Central/South Asian Heritage (HER)	1	1	0
Japanese/East Asian HER/South East Asian HER	25	24	23
American Indian or Alaska Native	0	1	0
American Indian or Alaska Native & White	14	12	13
African American / African HER	5	2	0
African American / African Heritage & White	0	1	0
Native Hawaiian or other Pacific Islander	0	0	0
Missing	0	0	0

Reporting group values	GW685698X 300 µg OD	GW685698X 400 µg OD	FP 250 µg BID
Number of subjects	103	99	100
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	39.9 ± 15.57	40.7 ± 15.87	39.8 ± 16.7
Gender categorical Units: Subjects			
Female	67	64	62
Male	36	35	38
Race, Customized Units: Subjects			
White	63	56	61
Central/South Asian Heritage (HER)	1	0	0
Japanese/East Asian HER/South East Asian HER	22	25	23
American Indian or Alaska Native	0	0	0
American Indian or Alaska Native & White	14	13	13
African American / African HER	2	4	3
African American / African Heritage & White	0	0	0
Native Hawaiian or other Pacific Islander	0	1	0
Missing	1	0	0

Reporting group values	Total		
Number of subjects	615		
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean			
---	--	--	--

standard deviation	-		
--------------------	---	--	--

Gender categorical			
Units: Subjects			
Female	402		
Male	213		
Race, Customized			
Units: Subjects			
White	371		
Central/South Asian Heritage (HER)	3		
Japanese/East Asian HER/South East Asian HER	142		
American Indian or Alaska Native	1		
American Indian or Alaska Native & White	79		
African American / African HER	16		
African American / African Heritage & White	1		
Native Hawaiian or other Pacific Islander	1		
Missing	1		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study.	
Reporting group title	GW685698X 100 µg OD
Reporting group description: Participants received GW685698X 100 micrograms (µg) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	
Reporting group title	GW685698X 200 µg OD
Reporting group description: Participants received GW685698X 200 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	
Reporting group title	GW685698X 300 µg OD
Reporting group description: Participants received GW685698X 300 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	
Reporting group title	GW685698X 400 µg OD
Reporting group description: Participants received GW685698X 400 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	
Reporting group title	FP 250 µg BID
Reporting group description: Participants received fluticasone propionate (FP) 250 µg BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.	

Primary: Mean change from Baseline in trough (evening pre-dose and pre- rescue bronchodilator) FEV1 at Week 8

End point title	Mean change from Baseline in trough (evening pre-dose and pre- rescue bronchodilator) FEV1 at Week 8
End point description: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. Pre-dose and pre-rescue bronchodilator (albuterol/salbutamol) trough FEV1 (the measurement of FEV1 performed at the end of the dosing interval) was measured electronically by spirometry in the evening at the Baseline (BL) through Week 8 clinic visits. The highest of 3 technically acceptable measurements was recorded. The Visit 3 FEV1 assessment was used as the BL value. Change from BL in trough FEV1 was calculated as the value at Week 8 minus the value at BL. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of BL trough FEV1, country, sex, age, and treatment group. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-BL on-treatment measurement (scheduled/unscheduled visits) was used to impute missing measurements.	
End point type	Primary

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106 ^[1]	102 ^[2]	101 ^[3]	102 ^[4]
Units: Liters				
least squares mean (standard error)	-0.065 (± 0.0395)	0.142 (± 0.0403)	0.173 (± 0.0404)	0.228 (± 0.0402)

Notes:

[1] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication.

[2] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication.

[3] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication.

[4] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	97 ^[5]	99 ^[6]		
Units: Liters				
least squares mean (standard error)	0.215 (± 0.0414)	0.16 (± 0.0409)		

Notes:

[5] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication.

[6] - Intent-to-Treat (ITT) Population: randomized participants who received ≥ 1 dose of study medication.

Statistical analyses

Statistical analysis title	Analysis 1
Comparison groups	Placebo v GW685698X 100 µg OD
Number of subjects included in analysis	208
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.207
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.096
upper limit	0.318

Statistical analysis title	Analysis 2
----------------------------	------------

Comparison groups	Placebo v GW685698X 200 µg OD
Number of subjects included in analysis	207
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.238
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.127
upper limit	0.349

Statistical analysis title	Analysis 3
Comparison groups	Placebo v GW685698X 300 µg OD
Number of subjects included in analysis	208
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.293
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.182
upper limit	0.404

Statistical analysis title	Analysis 4
Comparison groups	Placebo v GW685698X 400 µg OD
Number of subjects included in analysis	203
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.279
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.167
upper limit	0.392

Statistical analysis title	Analysis 5
Comparison groups	Placebo v FP 250 µg BID
Number of subjects included in analysis	205
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.225
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.114
upper limit	0.337

Secondary: Mean change from Baseline in daily trough (pre-dose and pre-rescue bronchodilator) evening peak expiratory flow (PEF) averaged over the 8-week Treatment Period

End point title	Mean change from Baseline in daily trough (pre-dose and pre-rescue bronchodilator) evening peak expiratory flow (PEF) averaged over the 8-week Treatment Period
-----------------	---

End point description:

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is defined as the PEF measurement performed at the end of the dosing interval. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three attempts was recorded by the participants in a daily diary. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily evening PEF over the 8-week treatment period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline trough evening PEF, country, sex, age, and treatment group.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[7]	104 ^[8]	101 ^[9]	102 ^[10]
Units: Liters per minute				
least squares mean (standard error)	-2.8 (± 3.54)	9.1 (± 3.6)	14.8 (± 3.65)	15.1 (± 3.62)

Notes:

[7] - ITT Population. Only those participants available at the specified time points were analyzed.

[8] - ITT Population. Only those participants available at the specified time points were analyzed.

[9] - ITT Population. Only those participants available at the specified time points were analyzed.

[10] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
-------------------------	------------------------	---------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[11]	99 ^[12]		
Units: Liters per minute				
least squares mean (standard error)	21 (± 3.7)	18.2 (± 3.69)		

Notes:

[11] - ITT Population. Only those participants available at the specified time points were analyzed.

[12] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in daily morning PEF averaged over the 8-week Treatment Period

End point title	Mean change from Baseline in daily morning PEF averaged over the 8-week Treatment Period
-----------------	--

End point description:

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is defined as the PEF measurement performed at the end of the dosing interval. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three attempts was recorded by the participants in a daily diary. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the value of the averaged daily morning PEF over the 8-week treatment period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline trough morning PEF, country, sex, age, and treatment group.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[13]	104 ^[14]	101 ^[15]	102 ^[16]
Units: Liters per minute				
least squares mean (standard error)	-4.7 (± 3.78)	15.6 (± 3.85)	16 (± 3.89)	25.5 (± 3.87)

Notes:

[13] - ITT Population. Only those participants available at the specified time points were analyzed.

[14] - ITT Population. Only those participants available at the specified time points were analyzed.

[15] - ITT Population. Only those participants available at the specified time points were analyzed.

[16] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[17]	99 ^[18]		
Units: Liters per minute				
least squares mean (standard error)	26 (± 3.95)	25.1 (± 3.94)		

Notes:

[17] - ITT Population. Only those participants available at the specified time points were analyzed.

[18] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in the percentage of symptom-free 24-hour (hr) periods during the 8-week Treatment Period

End point title	Mean change from Baseline in the percentage of symptom-free 24-hour (hr) periods during the 8-week Treatment Period
-----------------	---

End point description:

Asthma symptoms were recorded in a daily diary by the participants every day in the morning and evening before taking any rescue or study medication and before PEF measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered as symptom-free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 8-week Treatment Period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of Baseline, country, sex, age, and treatment group.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[19]	104 ^[20]	101 ^[21]	102 ^[22]
Units: Percentage of symptom-free 24-hr periods				
least squares mean (standard error)	17.1 (± 2.91)	21.3 (± 2.96)	19.4 (± 2.99)	24.1 (± 2.97)

Notes:

[19] - ITT Population. Only those participants available at the specified time points were analyzed.

[20] - ITT Population. Only those participants available at the specified time points were analyzed.

[21] - ITT Population. Only those participants available at the specified time points were analyzed.

[22] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[23]	99 ^[24]		
Units: Percentage of symptom-free 24-hr periods				
least squares mean (standard error)	28 (± 3.02)	30.4 (± 3.02)		

Notes:

[23] - ITT Population. Only those participants available at the specified time points were analyzed.

[24] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in the percentage of rescue free 24-hour (hr) periods during the 8-week Treatment Period

End point title	Mean change from Baseline in the percentage of rescue free 24-hour (hr) periods during the 8-week Treatment Period
-----------------	--

End point description:

The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily diary. A 24-hr period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue-free. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 8-week Treatment Period minus the value at Baseline. The analysis was performed using an ANCOVA model with covariates of baseline, country, sex, age, and treatment group.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[25]	104 ^[26]	101 ^[27]	102 ^[28]
Units: Percentage of rescue-free 24-hr periods				
least squares mean (standard error)	15.6 (± 3.02)	25 (± 3.07)	23.8 (± 3.12)	25 (± 3.1)

Notes:

[25] - ITT Population. Only those participants available at the specified time points were analyzed.

[26] - ITT Population. Only those participants available at the specified time points were analyzed.

[27] - ITT Population. Only those participants available at the specified time points were analyzed.

[28] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[29]	99 ^[30]		
Units: Percentage of rescue-free 24-hr periods				
least squares mean (standard error)	24.4 (± 3.15)	34.5 (± 3.15)		

Notes:

[29] - ITT Population. Only those participants available at the specified time points were analyzed.

[30] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants who withdrew due to lack of efficacy during the 8-Week Treatment Period

End point title	Number of participants who withdrew due to lack of efficacy during the 8-Week Treatment Period
-----------------	--

End point description:

The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study medication up to Week 8/Early Withdrawal

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[31]	105 ^[32]	101 ^[33]	103 ^[34]
Units: Participants	35	10	11	8

Notes:

[31] - ITT Population

[32] - ITT Population

[33] - ITT Population

[34] - ITT Population

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[35]	100 ^[36]		
Units: Participants	7	14		

Notes:

[35] - ITT Population

[36] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with any on-treatment adverse events or serious adverse events throughout the 8-week Treatment Period

End point title	Number of participants with any on-treatment adverse events or serious adverse events throughout the 8-week Treatment Period
-----------------	--

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should have been exercised in other situations. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold $\geq 3\%$) and SAEs.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study medication up to Week 8/Early Withdrawal

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[37]	105 ^[38]	101 ^[39]	103 ^[40]
Units: Participants				
Any AE	32	43	33	41
Any SAE	0	0	0	1

Notes:

[37] - ITT Population

[38] - ITT Population

[39] - ITT Population

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[41]	100 ^[42]		
Units: Participants				
Any AE	35	42		
Any SAE	1	0		

Notes:

[41] - ITT Population

[42] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with clinical/visual evidence of oropharyngeal candidiasis

End point title	Number of participants with clinical/visual evidence of oropharyngeal candidiasis
-----------------	---

End point description:

A detailed oropharyngeal examination for visual evidence of oral candidiasis was performed for the entire Treatment Period.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 8/Early Withdrawal

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[43]	105 ^[44]	101 ^[45]	103 ^[46]
Units: Participants				
Clinical evidence	0	3	2	4
No clinical evidence	107	102	99	99

Notes:

[43] - ITT Population

[44] - ITT Population

[45] - ITT Population

[46] - ITT Population

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[47]	100 ^[48]		
Units: Participants				
Clinical evidence	2	4		
No clinical evidence	97	96		

Notes:

[47] - ITT Population

[48] - ITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils in the blood at Baseline and Week 8

End point title	Percentage of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils in the blood at Baseline and Week 8
-----------------	---

End point description:

Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	100 ^[49]	103 ^[50]	97 ^[51]	99 ^[52]
Units: Percentage				
arithmetic mean (standard deviation)				
Basophils, BL, n=100, 103, 97, 99, 94, 95	0.33 (± 0.159)	0.32 (± 0.179)	0.35 (± 0.188)	0.31 (± 0.155)
Basophils, W8, n=63, 84, 82, 83, 81, 82	0.31 (± 0.182)	0.32 (± 0.191)	0.38 (± 0.227)	0.33 (± 0.165)
Eosinophils, BL, n=100, 103, 97, 99, 94, 95	4.48 (± 3.262)	4.05 (± 2.882)	4.05 (± 2.981)	4.17 (± 2.649)
Eosinophils, W8, n=63, 84, 82, 83, 81, 82	4.78 (± 4.107)	3.72 (± 2.518)	3.54 (± 2.556)	3.53 (± 2.671)
Lymphocytes, BL, n=100, 103, 97, 99, 94, 95	34.05 (± 9.683)	33.97 (± 8.817)	34.01 (± 9.214)	33.7 (± 8.38)
Lymphocytes, W8, n=63, 84, 82, 83, 81, 82	33.51 (± 8.261)	32.95 (± 8.183)	31.39 (± 8.668)	30.97 (± 8.711)
Monocytes, BL, n=100, 103, 97, 99, 94, 95	4.66 (± 1.674)	4.52 (± 2.128)	4.85 (± 1.939)	4.58 (± 1.994)
Monocytes, W8, n=63, 84, 82, 83, 81, 82	4.85 (± 1.798)	4.82 (± 3.006)	4.92 (± 2.324)	4.42 (± 1.833)
Total Neutrophils, BL, n=100, 103, 97, 99, 94, 95	56.46 (± 10.876)	57.12 (± 10.016)	56.72 (± 9.86)	57.22 (± 9.633)
Total Neutrophils, W8, n=63, 84, 82, 83, 81, 82	56.53 (± 9.391)	58.17 (± 9.386)	59.75 (± 9.513)	60.72 (± 9.846)

Notes:

[49] - ITT Population. Only those participants available at the specified time points were analyzed.

[50] - ITT Population. Only those participants available at the specified time points were analyzed.

[51] - ITT Population. Only those participants available at the specified time points were analyzed.

[52] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94 ^[53]	95 ^[54]		
Units: Percentage				
arithmetic mean (standard deviation)				
Basophils, BL, n=100, 103, 97, 99, 94, 95	0.33 (± 0.169)	0.34 (± 0.209)		
Basophils, W8, n=63, 84, 82, 83, 81, 82	0.32 (± 0.203)	0.35 (± 0.19)		
Eosinophils, BL, n=100, 103, 97, 99, 94, 95	4.2 (± 3.185)	4.66 (± 3.393)		
Eosinophils, W8, n=63, 84, 82, 83, 81, 82	3.35 (± 3.063)	4.21 (± 3.29)		
Lymphocytes, BL, n=100, 103, 97, 99, 94, 95	31.48 (± 9.075)	33.61 (± 9.032)		
Lymphocytes, W8, n=63, 84, 82, 83, 81, 82	27.38 (± 7.585)	33.17 (± 7.607)		
Monocytes, BL, n=100, 103, 97, 99, 94, 95	4.47 (± 1.954)	4.55 (± 2.19)		
Monocytes, W8, n=63, 84, 82, 83, 81, 82	4.18 (± 2.176)	4.59 (± 2.436)		
Total Neutrophils, BL, n=100, 103, 97, 99, 94, 95	59.5 (± 10.248)	56.75 (± 10.915)		
Total Neutrophils, W8, n=63, 84, 82, 83, 81, 82	64.75 (± 8.896)	57.61 (± 9.681)		

Notes:

[53] - ITT Population. Only those participants available at the specified time points were analyzed.

[54] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Hematocrit at Baseline and Week 8

End point title	Hematocrit at Baseline and Week 8
End point description:	Blood samples were collected for the measurement of Hematocrit at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).
End point type	Secondary
End point timeframe:	Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	102 ^[55]	104 ^[56]	96 ^[57]	99 ^[58]
Units: Proportion of 1				
arithmetic mean (standard deviation)				
Hematocrit, BL, n=102, 104, 96, 99, 93, 95	0.42 (± 0.041)	0.43 (± 0.034)	0.42 (± 0.043)	0.42 (± 0.035)
Hematocrit, W8, n=62, 84, 82, 83, 81, 81	0.41 (± 0.037)	0.42 (± 0.039)	0.42 (± 0.043)	0.41 (± 0.038)

Notes:

- [55] - ITT Population. Only those participants available at the specified time points were analyzed.
 [56] - ITT Population. Only those participants available at the specified time points were analyzed.
 [57] - ITT Population. Only those participants available at the specified time points were analyzed.
 [58] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93 ^[59]	95 ^[60]		
Units: Proportion of 1				
arithmetic mean (standard deviation)				
Hematocrit, BL, n=102, 104, 96, 99, 93, 95	0.42 (± 0.039)	0.42 (± 0.039)		
Hematocrit, W8, n=62, 84, 82, 83, 81, 81	0.42 (± 0.046)	0.41 (± 0.055)		

Notes:

- [59] - ITT Population. Only those participants available at the specified time points were analyzed.
 [60] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Hemoglobin at Baseline and Week 8

End point title	Hemoglobin at Baseline and Week 8
End point description:	
Blood samples were collected for the measurement of hemoglobin at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).	
End point type	Secondary
End point timeframe:	
Baseline and Week 8	

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	102 ^[61]	104 ^[62]	96 ^[63]	99 ^[64]
Units: Grams per liter (G/L)				
arithmetic mean (standard deviation)				
Hemoglobin, BL, n=102, 104, 96, 99, 93, 95	137.64 (± 13.911)	139.34 (± 11.908)	137.74 (± 14.028)	138.08 (± 11.707)
Hemoglobin, W8, n=62, 84, 82, 83, 81, 81	135.09 (± 12.043)	136.42 (± 13.342)	137.85 (± 13.772)	135.3 (± 12.36)

Notes:

- [61] - ITT Population. Only those participants available at the specified time points were analyzed.
 [62] - ITT Population. Only those participants available at the specified time points were analyzed.
 [63] - ITT Population. Only those participants available at the specified time points were analyzed.
 [64] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
------------------	------------------------	---------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93 ^[65]	95 ^[66]		
Units: Grams per liter (G/L)				
arithmetic mean (standard deviation)				
Hemoglobin, BL, n=102, 104, 96, 99, 93, 95	138.57 (± 13.393)	136.93 (± 14.139)		
Hemoglobin, W8, n=62, 84, 82, 83, 81, 81	138.17 (± 15.05)	135.79 (± 18.663)		

Notes:

[65] - ITT Population. Only those participants available at the specified time points were analyzed.

[66] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Platelet count and white blood cell (WBC) count at Baseline and Week 8

End point title	Platelet count and white blood cell (WBC) count at Baseline and Week 8
End point description:	Blood samples were collected for the measurement of platelet count and WBC count at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).
End point type	Secondary
End point timeframe:	Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	101 ^[67]	103 ^[68]	96 ^[69]	99 ^[70]
Units: 10 ⁹ cells per liter (GI/L)				
arithmetic mean (standard deviation)				
Platelet count, BL, n=98, 103, 93, 98, 89, 94	286.23 (± 57.383)	277.29 (± 64.358)	290.9 (± 98.801)	282.86 (± 70.086)
Platelet count, W8, n=60, 84, 80, 81, 80, 80	275.91 (± 53.705)	281.4 (± 66.449)	277.73 (± 71.595)	287.98 (± 67.053)
WBC, BL, n=101, 103, 96, 99, 93, 95	8.05 (± 2.31)	7.9 (± 2.11)	7.69 (± 2.086)	8.11 (± 2.332)
WBC, W8, n=62, 84, 82, 83, 81, 81	8.02 (± 1.991)	8.06 (± 1.894)	7.79 (± 2.066)	8.2 (± 1.936)

Notes:

[67] - ITT Population. Only those participants available at the specified time points were analyzed.

[68] - ITT Population. Only those participants available at the specified time points were analyzed.

[69] - ITT Population. Only those participants available at the specified time points were analyzed.

[70] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93 ^[71]	95 ^[72]		
Units: 10 ⁹ cells per liter (GI/L)				
arithmetic mean (standard deviation)				
Platelet count, BL, n=98, 103, 93, 98, 89, 94	283.01 (± 58.915)	285.45 (± 69.22)		

Platelet count, W8, n=60, 84, 80, 81, 80, 80	297.83 (\pm 76.271)	287.6 (\pm 87.009)		
WBC, BL, n=101, 103, 96, 99, 93, 95	8.23 (\pm 2.027)	8.12 (\pm 2.141)		
WBC, W8, n=62, 84, 82, 83, 81, 81	9.07 (\pm 2.054)	8.3 (\pm 3.119)		

Notes:

[71] - ITT Population. Only those participants available at the specified time points were analyzed.

[72] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Red blood cells (RBC) count at Baseline and Week 8

End point title	Red blood cells (RBC) count at Baseline and Week 8
-----------------	--

End point description:

Blood samples were collected for the measurement of RBC count at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	102 ^[73]	104 ^[74]	96 ^[75]	99 ^[76]
Units: 10 ¹² cells per liter (TI/L)				
arithmetic mean (standard deviation)				
BL, n=102, 104, 96, 99, 93, 95	4.66 (\pm 0.439)	4.68 (\pm 0.385)	4.69 (\pm 0.539)	4.63 (\pm 0.442)
W8, n=62, 84, 82, 83, 81, 80	4.54 (\pm 0.483)	4.57 (\pm 0.447)	4.62 (\pm 0.513)	4.5 (\pm 0.458)

Notes:

[73] - ITT Population. Only those participants available at the specified time points were analyzed.

[74] - ITT Population. Only those participants available at the specified time points were analyzed.

[75] - ITT Population. Only those participants available at the specified time points were analyzed.

[76] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93 ^[77]	95 ^[78]		
Units: 10 ¹² cells per liter (TI/L)				
arithmetic mean (standard deviation)				
BL, n=102, 104, 96, 99, 93, 95	4.64 (\pm 0.395)	4.61 (\pm 0.412)		
W8, n=62, 84, 82, 83, 81, 80	4.66 (\pm 0.526)	4.52 (\pm 0.426)		

Notes:

[77] - ITT Population. Only those participants available at the specified time points were analyzed.

[78] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical chemistry parameters of alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LD), and gamma glutamyltransferase (GGT) at Baseline and Week 8

End point title	Clinical chemistry parameters of alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LD), and gamma glutamyltransferase (GGT) at Baseline and Week 8
End point description:	
Blood samples were collected for the measurement of ALP, ALT, AST, LD and GGT at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at Screening (Visit 1).	
End point type	Secondary
End point timeframe:	
Baseline and Week 8	

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106 ^[79]	104 ^[80]	101 ^[81]	102 ^[82]
Units: International units per liter (IU/L)				
arithmetic mean (standard deviation)				
ALP, BL, n=106, 104, 101, 102, 98, 99	89.3 (± 58.42)	90.5 (± 61.69)	83.7 (± 56.68)	88 (± 74.76)
ALP, W8, n=65, 85, 84, 89, 83, 81	88 (± 57.32)	82.8 (± 44.87)	77.9 (± 40.64)	77.9 (± 37.21)
ALT, BL, n=106, 104, 101, 102, 98, 99	22.3 (± 21.25)	20 (± 14.75)	20.5 (± 15.44)	23.4 (± 15.65)
ALT, W8, n=65, 85, 85, 89, 83, 81	20.1 (± 14.37)	21 (± 14.01)	20.8 (± 11.68)	23.3 (± 16.73)
AST, BL, n=106, 103, 100, 102, 97, 99	25.2 (± 30.81)	20.8 (± 7.81)	24.8 (± 38.56)	22.7 (± 10.1)
AST, W8, n=65, 85, 85, 89, 83, 81	21.8 (± 8.77)	20.5 (± 7.5)	21.4 (± 8.42)	22.7 (± 12.58)
LD, BL, n=106, 103, 100, 102, 97, 99	173.2 (± 66.73)	167.1 (± 44.88)	173.8 (± 129.22)	169 (± 54.06)
LD, W8, n=65, 85, 85, 89, 83, 81	157.4 (± 37.93)	158.2 (± 29.31)	162.5 (± 35.17)	160.6 (± 30.45)
GGT, BL, n=106, 104, 101, 102, 98, 99	33.1 (± 54.48)	26 (± 20.33)	27.6 (± 21.53)	35.2 (± 38.16)
GGT, W8, n=65, 85, 85, 89, 83, 81	31.5 (± 44.86)	30.1 (± 41.05)	29.2 (± 31.63)	34.8 (± 39.4)

Notes:

[79] - ITT Population. Only those participants available at the specified time points were analyzed.

[80] - ITT Population. Only those participants available at the specified time points were analyzed.

[81] - ITT Population. Only those participants available at the specified time points were analyzed.

[82] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	98 ^[83]	99 ^[84]		
Units: International units per liter (IU/L)				
arithmetic mean (standard deviation)				
ALP, BL, n=106, 104, 101, 102, 98, 99	83.8 (± 40.51)	89 (± 57.83)		
ALP, W8, n=65, 85, 84, 89, 83, 81	81.9 (± 40.05)	88.6 (± 53.16)		
ALT, BL, n=106, 104, 101, 102, 98, 99	20.4 (± 12.7)	20.6 (± 15.83)		
ALT, W8, n=65, 85, 85, 89, 83, 81	22.1 (± 18.46)	20.3 (± 14.92)		
AST, BL, n=106, 103, 100, 102, 97, 99	21.2 (± 7.1)	21.4 (± 10.18)		
AST, W8, n=65, 85, 85, 89, 83, 81	21.7 (± 8.87)	21.4 (± 8.51)		
LD, BL, n=106, 103, 100, 102, 97, 99	168.6 (± 50.65)	167.1 (± 57.95)		

LD, W8, n=65, 85, 85, 89, 83, 81	169.2 (± 31.91)	162.4 (± 35.39)		
GGT, BL, n=106, 104, 101, 102, 98, 99	28.2 (± 18.36)	29.5 (± 27.6)		
GGT, W8, n=65, 85, 85, 89, 83, 81	28.3 (± 23.69)	28.4 (± 24.14)		

Notes:

[83] - ITT Population. Only those participants available at the specified time points were analyzed.

[84] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical chemistry parameters of albumin and total protein at Baseline and Week 8

End point title	Clinical chemistry parameters of albumin and total protein at Baseline and Week 8
End point description:	
Blood samples were collected for the measurement of albumin and total protein at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at Screening (Visit 1).	
End point type	Secondary
End point timeframe:	
Baseline and Week 8	

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106 ^[85]	104 ^[86]	101 ^[87]	102 ^[88]
Units: Grams per liter (G/L)				
arithmetic mean (standard deviation)				
Albumin, BL, n=106, 104, 101, 102, 98, 99	45.2 (± 3.43)	45.4 (± 3.12)	45.4 (± 3.16)	45.4 (± 2.71)
Albumin, W8, n=65, 85, 85, 89, 83, 81	44 (± 3.06)	44.7 (± 3.08)	45.1 (± 2.81)	44.6 (± 2.81)
Total protein, BL, n=106, 104, 101, 102, 98, 99	74.1 (± 5.03)	73.3 (± 4.16)	73.9 (± 4.4)	73.7 (± 4.42)
Total protein, W8, n=65, 85, 85, 89, 83, 81	72 (± 4.68)	72.4 (± 4.31)	73.3 (± 5.28)	72.5 (± 3.92)

Notes:

[85] - ITT Population. Only those participants available at the specified time points were analyzed.

[86] - ITT Population. Only those participants available at the specified time points were analyzed.

[87] - ITT Population. Only those participants available at the specified time points were analyzed.

[88] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	98 ^[89]	99 ^[90]		
Units: Grams per liter (G/L)				
arithmetic mean (standard deviation)				
Albumin, BL, n=106, 104, 101, 102, 98, 99	45.5 (± 2.62)	44.9 (± 2.86)		
Albumin, W8, n=65, 85, 85, 89, 83, 81	45.3 (± 2.91)	44.5 (± 3.19)		
Total protein, BL, n=106, 104, 101, 102, 98, 99	74 (± 4.37)	73 (± 4.26)		

Total protein, W8, n=65, 85, 85, 89, 83, 81	73.9 (± 4.02)	72.8 (± 4.16)		
---	---------------	---------------	--	--

Notes:

[89] - ITT Population. Only those participants available at the specified time points were analyzed.

[90] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical chemistry parameters of chloride, calcium, carbon dioxide content/bicarbonate (CO₂/BI), cholesterol, glucose, phosphorus inorganic(PI), potassium, sodium, and urea/blood urea nitrogen (BUN) at Baseline and Week 8

End point title	Clinical chemistry parameters of chloride, calcium, carbon dioxide content/bicarbonate (CO ₂ /BI), cholesterol, glucose, phosphorus inorganic(PI), potassium, sodium, and urea/blood urea nitrogen (BUN) at Baseline and Week 8
-----------------	--

End point description:

Blood samples were collected for the measurement of chloride, calcium, CO₂/BI, cholesterol, glucose, PI, potassium, sodium, and urea/blood urea nitrogen (BUN) at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106 ^[91]	104 ^[92]	101 ^[93]	102 ^[94]
Units: Millimoles per liter (mmol/L)				
arithmetic mean (standard deviation)				
Chloride, BL, n=106, 104, 101, 102, 98, 99	104.8 (± 3.06)	105 (± 2.61)	104.7 (± 3.15)	104.5 (± 2.34)
Chloride, W8, n=65, 85, 85, 89, 83, 81	104.8 (± 2.31)	104.3 (± 2.05)	104.3 (± 2.36)	104.4 (± 2.2)
Calcium, BL, n=106, 103, 100, 102, 97, 99	2.3 (± 0.12)	2.3 (± 0.12)	2.3 (± 0.12)	2.3 (± 0.1)
Calcium, W8, n=65, 85, 84, 89, 83, 81	2.3 (± 0.12)	2.3 (± 0.12)	2.3 (± 0.11)	2.3 (± 0.11)
CO ₂ /BI, BL, n=106, 103, 100, 102, 97, 99	22.9 (± 2.12)	22.5 (± 2.67)	22.7 (± 2.4)	22.6 (± 2.58)
CO ₂ /BI, W8, n=65, 85, 85, 89, 83, 81	22.4 (± 2.08)	22.5 (± 2.4)	22.8 (± 2.72)	23.1 (± 2.4)
Cholesterol, BL, n=106, 104, 101, 102, 98, 99	5 (± 1.09)	5 (± 1.21)	4.9 (± 1.07)	5.2 (± 1.13)
Cholesterol, W8, n=65, 85, 85, 89, 83, 81	4.9 (± 1.06)	5 (± 1.19)	4.9 (± 1.03)	5.1 (± 1.08)
Glucose, BL, n=106, 103, 100, 102, 98, 99	5.2 (± 0.94)	5.4 (± 1.95)	5.1 (± 0.7)	5.2 (± 0.84)
Glucose, W8, n=65, 85, 85, 89, 83, 81	5 (± 0.73)	5.2 (± 1.66)	5.1 (± 1.04)	5.2 (± 1.06)
PI, BL, n=106, 104, 101, 102, 98, 99	1.2 (± 0.2)	1.2 (± 0.22)	1.2 (± 0.33)	1.2 (± 0.19)
PI, W8, n=65, 85, 85, 89, 83, 81	1.3 (± 0.21)	1.3 (± 0.17)	1.2 (± 0.18)	1.2 (± 0.17)
Potassium, BL, n=106, 103, 100, 102, 97, 99	4.2 (± 0.41)	4.1 (± 0.45)	4.1 (± 0.44)	4.2 (± 0.46)
Potassium, W8, n=65, 85, 84, 89, 83, 81	4.2 (± 0.64)	4.2 (± 0.53)	4.3 (± 0.63)	4.2 (± 0.44)

Sodium, BL, n=106, 104, 101, 102, 98, 99	140.7 (± 3.38)	140.6 (± 1.91)	141 (± 3.13)	140.3 (± 2.07)
Sodium, W8, n=65, 85, 85, 89, 83, 81	139.9 (± 2.11)	140 (± 1.95)	140.3 (± 2.05)	140.5 (± 2.15)
BUN, BL, n=106, 104, 101, 102, 98, 99	5.3 (± 1.87)	5.1 (± 2.07)	5.1 (± 1.9)	4.9 (± 1.61)
BUN, W8, n=65, 85, 85, 89, 83, 81	5.2 (± 1.42)	4.9 (± 1.47)	5 (± 1.61)	5 (± 1.68)

Notes:

[91] - ITT Population. Only those participants available at the specified time points were analyzed.

[92] - ITT Population. Only those participants available at the specified time points were analyzed.

[93] - ITT Population. Only those participants available at the specified time points were analyzed.

[94] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	98 ^[95]	99 ^[96]		
Units: Millimoles per liter (mmol/L)				
arithmetic mean (standard deviation)				
Chloride, BL, n=106, 104, 101, 102, 98, 99	104.8 (± 3)	105 (± 2.41)		
Chloride, W8, n=65, 85, 85, 89, 83, 81	104 (± 2.37)	104.4 (± 2.37)		
Calcium, BL, n=106, 103, 100, 102, 97, 99	2.3 (± 0.12)	2.3 (± 0.11)		
Calcium, W8, n=65, 85, 84, 89, 83, 81	2.3 (± 0.12)	2.3 (± 0.11)		
CO2/BI, BL, n=106, 103, 100, 102, 97, 99	22.6 (± 2.24)	22.6 (± 2.15)		
CO2/BI, W8, n=65, 85, 85, 89, 83, 81	22.8 (± 2.58)	22.9 (± 2.37)		
Cholesterol, BL, n=106, 104, 101, 102, 98, 99	5.2 (± 1.16)	5 (± 1.12)		
Cholesterol, W8, n=65, 85, 85, 89, 83, 81	5.1 (± 1.11)	4.9 (± 1.05)		
Glucose, BL, n=106, 103, 100, 102, 98, 99	5.5 (± 2.18)	5.5 (± 1.88)		
Glucose, W8, n=65, 85, 85, 89, 83, 81	5 (± 1.46)	5.3 (± 1.85)		
PI, BL, n=106, 104, 101, 102, 98, 99	1.2 (± 0.19)	1.1 (± 0.22)		
PI, W8, n=65, 85, 85, 89, 83, 81	1.3 (± 0.26)	1.3 (± 0.19)		
Potassium, BL, n=106, 103, 100, 102, 97, 99	4.2 (± 0.38)	4.1 (± 0.41)		
Potassium, W8, n=65, 85, 84, 89, 83, 81	4.3 (± 0.66)	4.2 (± 0.34)		
Sodium, BL, n=106, 104, 101, 102, 98, 99	140.7 (± 2.85)	140.5 (± 1.76)		
Sodium, W8, n=65, 85, 85, 89, 83, 81	140.3 (± 2.23)	140.2 (± 1.8)		
BUN, BL, n=106, 104, 101, 102, 98, 99	5.2 (± 2.2)	5.3 (± 1.78)		
BUN, W8, n=65, 85, 85, 89, 83, 81	4.8 (± 1.6)	5.2 (± 1.64)		

Notes:

[95] - ITT Population. Only those participants available at the specified time points were analyzed.

[96] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical chemistry parameters of direct bilirubin (DBIL), total bilirubin (TBIL), uric acid and creatinine at Baseline and Week 8

End point title	Clinical chemistry parameters of direct bilirubin (DBIL), total bilirubin (TBIL), uric acid and creatinine at Baseline and Week 8
-----------------	---

End point description:

Blood samples were collected for the measurement of DBIL, TBIL, uric acid and creatinine at Baseline (BL) and Week 8 (W8). The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106 ^[97]	104 ^[98]	101 ^[99]	102 ^[100]
Units: Micromoles per liter (µmol/L)				
arithmetic mean (standard deviation)				
DBIL, BL, n=106, 103, 100, 101, 98, 98	2.1 (± 1.23)	2 (± 1.3)	1.9 (± 1.09)	1.9 (± 1.09)
DBIL, W8, n=65, 65, 85, 89, 83, 81	1.8 (± 0.97)	2 (± 1.09)	1.9 (± 0.88)	1.9 (± 1.18)
TBIL, BL, n=106, 104, 101, 102, 98, 99	10.2 (± 5.39)	10.6 (± 6.11)	9.4 (± 5.2)	9.3 (± 4.65)
TBIL, W8, n=65, 85, 85, 89, 83, 81	8.5 (± 4.38)	9.6 (± 6.13)	9.2 (± 4.93)	8.8 (± 4.14)
Uric acid, BL, n=106, 104, 101, 102, 98, 99	326.7 (± 93.33)	323.2 (± 83.6)	319.4 (± 94.9)	326.7 (± 95.36)
Uric acid, W8, n=65, 85, 85, 89, 83, 81	308.8 (± 89.18)	318.3 (± 84.85)	319.7 (± 93.76)	314.4 (± 94.26)
Creatinine, BL, n=106, 104, 101, 102, 98, 99	77.9 (± 14.57)	77.9 (± 18.6)	77.8 (± 16.5)	75.9 (± 15.04)
Creatinine, W8, n=65, 85, 85, 89, 83, 81	74.4 (± 15.58)	74.6 (± 14.95)	78.5 (± 16.79)	76.9 (± 15.97)

Notes:

[97] - ITT Population. Only those participants available at the specified time points were analyzed.

[98] - ITT Population. Only those participants available at the specified time points were analyzed.

[99] - ITT Population. Only those participants available at the specified time points were analyzed.

[100] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	98 ^[101]	99 ^[102]		
Units: Micromoles per liter (µmol/L)				
arithmetic mean (standard deviation)				
DBIL, BL, n=106, 103, 100, 101, 98, 98	2.1 (± 0.97)	1.8 (± 0.9)		
DBIL, W8, n=65, 65, 85, 89, 83, 81	1.8 (± 0.93)	1.7 (± 0.75)		
TBIL, BL, n=106, 104, 101, 102, 98, 99	9.7 (± 5.48)	8.9 (± 4.02)		
TBIL, W8, n=65, 85, 85, 89, 83, 81	9.2 (± 4.08)	8.4 (± 3.03)		
Uric acid, BL, n=106, 104, 101, 102, 98, 99	323.9 (± 82.3)	312.7 (± 85.72)		
Uric acid, W8, n=65, 85, 85, 89, 83, 81	321.1 (± 83.68)	311.4 (± 90.62)		
Creatinine, BL, n=106, 104, 101, 102, 98, 99	75.9 (± 18.24)	77.7 (± 15.77)		
Creatinine, W8, n=65, 85, 85, 89, 83, 81	76.2 (± 15.18)	77.2 (± 16.59)		

Notes:

[101] - ITT Population. Only those participants available at the specified time points were analyzed.

[102] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with the indicated result for the indicated urinalysis parameters tested by dipstick at Baseline and Week 8/Early Withdrawal

End point title	Number of participants with the indicated result for the indicated urinalysis parameters tested by dipstick at Baseline and Week 8/Early Withdrawal
-----------------	---

End point description:

Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative (Neg), Trace, 1+, 2+, 3+ and 4+, and for UG the result can be read as Neg, Trace, Trace or 1/10 grams per deciliter (G/dL), 1+ or 1/4 G/dL, 3+ or 1 G/dL, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, Trace, 1+, 2+, 3+ and 4+ levels at Baseline (BL) and Week 8 (W8)/Early Withdrawal (WD). The Baseline value was the measurement taken at screening (Visit 1).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8/Early Withdrawal

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	102 ^[103]	101 ^[104]	98 ^[105]	99 ^[106]
Units: Participants				
UOB, Neg, BL, n=102, 101, 98, 99, 94, 97	96	91	85	90
UOB, Trace, BL, n=102, 101, 98, 99, 94, 97	4	1	3	4
UOB, 1+, BL, n=102, 101, 98, 99, 94, 97	1	4	6	1
UOB, 2+, BL, n=102, 101, 98, 99, 94, 97	0	1	1	0
UOB, 3+, BL, n=102, 101, 98, 99, 94, 97	1	4	3	4
UOB, Neg, W8, n=63, 85, 84, 82, 82, 82	56	77	77	73
UOB, Trace, W8, n=63, 85, 84, 82, 82, 82	4	3	2	3
UOB, 1+, W8, n=63, 85, 84, 82, 82, 82	0	2	1	1
UOB, 2+, W8, n=63, 85, 84, 82, 82, 82	1	1	2	1
UOB, 3+, W8, n=63, 85, 84, 82, 82, 82	2	2	2	4
UOB, Neg, WD, n=9, 4, 1, 2, 3, 7	9	4	1	2
UOB, 2+, WD, n=9, 4, 1, 2, 3, 7	0	0	0	0
UG, Neg, BL, n=102, 101, 98, 99, 94, 97	100	98	98	98
UG, Trace, BL, n=102, 101, 98, 99, 94, 97	1	1	0	0
UG, Trace or 1/10 G/dL, BL, n=102, 101, 98, 99, 94, 97	1	0	0	0
UG, 1+ or 1/3 G/dL, BL, n=102, 101, 98, 99, 94, 97	0	0	0	1

UG, 3+ or 1 G/DL, BL, n=102, 101, 98, 99, 94, 97	0	2	0	0
UG, Neg, W8, n=63, 85, 84, 82, 82, 82	62	83	83	81
UG, Trace, W8, n=63, 85, 84, 82, 82, 82	0	0	1	1
UG, 1+ or 1/4 G/DL, W8, n=63, 85, 84, 82, 82, 82	1	0	0	0
UG, 3+ or 1 G/DL, W8, n=63, 85, 84, 82, 82, 82	0	2	0	0
UG, Neg, WD, n=9, 4, 1, 2, 3, 7	9	4	1	2
UK, Neg, BL, n=102, 101, 98, 99, 94, 97	97	96	96	96
UK, Trace, BL, n=102, 101, 98, 99, 94, 97	5	2	2	3
UK, 1+, BL, n=102, 101, 98, 99, 94, 97	0	2	0	0
UK, 2+, BL, n=102, 101, 98, 99, 94, 97	0	1	0	0
UK, Neg, W8, n=63, 85, 84, 82, 82, 82	61	80	81	78
UK, Trace, W8, n=63, 85, 84, 82, 82, 82	2	5	2	4
UK, 1+, W8, n=63, 85, 84, 82, 82, 82	0	0	1	0
UK, Neg, WD, n=9, 4, 1, 2, 3, 7	9	4	1	2
UP, Neg, BL, n=102, 101, 98, 99, 94, 97	76	78	77	78
UP, Trace, BL, n=102, 101, 98, 99, 94, 97	19	14	13	13
UP, 1+, BL, n=102, 101, 98, 99, 94, 97	6	6	7	7
UP, 2+, BL, n=102, 101, 98, 99, 94, 97	0	1	1	0
UP, 3+, BL, n=102, 101, 98, 99, 94, 97	1	2	0	1
UP, Neg, W8, n=63, 85, 84, 82, 82, 82	54	64	68	65
UP, Trace, W8, n=63, 85, 84, 82, 82, 82	6	14	8	12
UP, 1+, W8, n=63, 85, 84, 82, 82, 82	3	5	6	5
UP, 2+, W8, n=63, 85, 84, 82, 82, 82	0	2	1	0
UP, 3+, W8, n=63, 85, 84, 82, 82, 82	0	0	0	0
UP, 4+, W8, n=63, 85, 84, 82, 82, 82	0	0	1	0
UP, Neg, WD, n=9, 4, 1, 2, 3, 7	8	4	0	1
UP, Trace, WD, n=9, 4, 1, 2, 3, 7	0	0	1	1
UP, 1+, WD, n=9, 4, 1, 2, 3, 7	1	0	0	0
UWBC, Neg, BL, n=102, 101, 98, 99, 94, 97	86	87	82	81
UWBC, Trace, BL, n=102, 101, 98, 99, 94, 97	2	4	7	3
UWBC, 1+, BL, n=102, 101, 98, 99, 94, 97	6	5	4	7
UWBC, 2+, BL, n=102, 101, 98, 99, 94, 97	7	3	2	8
UWBC, 3+, BL, n=102, 101, 98, 99, 94, 97	1	2	3	0
UWBC, Neg, W8, n=63, 85, 84, 82, 82, 82	52	65	71	62
UWBC, Trace, W8, n=63, 85, 84, 82, 82, 82	3	5	4	7
UWBC, 1+, W8, n=63, 85, 84, 82, 82, 82	7	7	6	7
UWBC, 2+, W8, n=63, 85, 84, 82, 82, 82	1	7	3	5
UWBC, 3+, W8, n=63, 85, 84, 82, 82, 82	0	1	0	1
UWBC, Neg, WD, n=9, 4, 1, 2, 3, 7	9	4	0	1

UWBC, 2+, WD, n=9, 4, 1, 2, 3, 7	0	0	1	1
----------------------------------	---	---	---	---

Notes:

[103] - ITT Population. Only those participants available at the specified time points were analyzed.

[104] - ITT Population. Only those participants available at the specified time points were analyzed.

[105] - ITT Population. Only those participants available at the specified time points were analyzed.

[106] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94 ^[107]	97 ^[108]		
Units: Participants				
UOB, Neg, BL, n=102, 101, 98, 99, 94, 97	81	91		
UOB, Trace, BL, n=102, 101, 98, 99, 94, 97	8	2		
UOB, 1+, BL, n=102, 101, 98, 99, 94, 97	1	1		
UOB, 2+, BL, n=102, 101, 98, 99, 94, 97	0	1		
UOB, 3+, BL, n=102, 101, 98, 99, 94, 97	4	2		
UOB, Neg, W8, n=63, 85, 84, 82, 82, 82	73	72		
UOB, Trace, W8, n=63, 85, 84, 82, 82, 82	2	4		
UOB, 1+, W8, n=63, 85, 84, 82, 82, 82	3	1		
UOB, 2+, W8, n=63, 85, 84, 82, 82, 82	3	1		
UOB, 3+, W8, n=63, 85, 84, 82, 82, 82	1	4		
UOB, Neg, WD, n=9, 4, 1, 2, 3, 7	3	6		
UOB, 2+, WD, n=9, 4, 1, 2, 3, 7	0	1		
UG, Neg, BL, n=102, 101, 98, 99, 94, 97	91	94		
UG, Trace, BL, n=102, 101, 98, 99, 94, 97	0	0		
UG, Trace or 1/10 G/DL, BL, n=102, 101, 98, 99, 94, 97	0	1		
UG, 1+ or 1/3 G/DL, BL, n=102, 101, 98, 99, 94, 97	1	1		
UG, 3+ or 1 G/DL, BL, n=102, 101, 98, 99, 94, 97	2	1		
UG, Neg, W8, n=63, 85, 84, 82, 82, 82	82	80		
UG, Trace, W8, n=63, 85, 84, 82, 82, 82	0	0		
UG, 1+ or 1/4 G/DL, W8, n=63, 85, 84, 82, 82, 82	0	0		
UG, 3+ or 1 G/DL, W8, n=63, 85, 84, 82, 82, 82	0	2		
UG, Neg, WD, n=9, 4, 1, 2, 3, 7	3	7		
UK, Neg, BL, n=102, 101, 98, 99, 94, 97	90	94		
UK, Trace, BL, n=102, 101, 98, 99, 94, 97	4	1		
UK, 1+, BL, n=102, 101, 98, 99, 94, 97	0	2		
UK, 2+, BL, n=102, 101, 98, 99, 94, 97	0	0		
UK, Neg, W8, n=63, 85, 84, 82, 82, 82	75	80		
UK, Trace, W8, n=63, 85, 84, 82, 82, 82	7	2		

UK, 1+, W8, n=63, 85, 84, 82, 82, 82	0	0		
UK, Neg, WD, n=9, 4, 1, 2, 3, 7	3	7		
UP, Neg, BL, n=102, 101, 98, 99, 94, 97	70	75		
UP, Trace, BL, n=102, 101, 98, 99, 94, 97	17	11		
UP, 1+, BL, n=102, 101, 98, 99, 94, 97	6	11		
UP, 2+, BL, n=102, 101, 98, 99, 94, 97	1	0		
UP, 3+, BL, n=102, 101, 98, 99, 94, 97	0	0		
UP, Neg, W8, n=63, 85, 84, 82, 82, 82	63	61		
UP, Trace, W8, n=63, 85, 84, 82, 82, 82	17	15		
UP, 1+, W8, n=63, 85, 84, 82, 82, 82	2	5		
UP, 2+, W8, n=63, 85, 84, 82, 82, 82	0	0		
UP, 3+, W8, n=63, 85, 84, 82, 82, 82	0	1		
UP, 4+, W8, n=63, 85, 84, 82, 82, 82	0	0		
UP, Neg, WD, n=9, 4, 1, 2, 3, 7	3	6		
UP, Trace, WD, n=9, 4, 1, 2, 3, 7	0	0		
UP, 1+, WD, n=9, 4, 1, 2, 3, 7	0	1		
UWBC, Neg, BL, n=102, 101, 98, 99, 94, 97	74	88		
UWBC, Trace, BL, n=102, 101, 98, 99, 94, 97	5	2		
UWBC, 1+, BL, n=102, 101, 98, 99, 94, 97	8	3		
UWBC, 2+, BL, n=102, 101, 98, 99, 94, 97	5	4		
UWBC, 3+, BL, n=102, 101, 98, 99, 94, 97	2	0		
UWBC, Neg, W8, n=63, 85, 84, 82, 82, 82	63	69		
UWBC, Trace, W8, n=63, 85, 84, 82, 82, 82	7	3		
UWBC, 1+, W8, n=63, 85, 84, 82, 82, 82	5	7		
UWBC, 2+, W8, n=63, 85, 84, 82, 82, 82	7	3		
UWBC, 3+, W8, n=63, 85, 84, 82, 82, 82	0	0		
UWBC, Neg, WD, n=9, 4, 1, 2, 3, 7	3	7		
UWBC, 2+, WD, n=9, 4, 1, 2, 3, 7	0	0		

Notes:

[107] - ITT Population. Only those participants available at the specified time points were analyzed.

[108] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Urine specific gravity at Baseline and Week 8/Early Withdrawal

End point title	Urine specific gravity at Baseline and Week 8/Early Withdrawal
-----------------	--

End point description:

Urine samples were collected for the measurement of urine specific gravity by dipstick method at Baseline and at Week 8/Early Withdrawal. The Baseline value was the measurement taken at screening (Visit 1). Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance. Normal urine has a specific gravity between 1.010 and 1.020.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8/Early Withdrawal

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	102 ^[109]	104 ^[110]	96 ^[111]	99 ^[112]
Units: ratio				
arithmetic mean (standard deviation)				
BL, n=102, 101, 98, 99, 94, 97	1.0232 (± 0.00741)	1.0227 (± 0.00687)	1.0226 (± 0.00718)	1.0224 (± 0.00719)
W8, n=63, 85, 84, 82, 82, 82	1.0225 (± 0.00778)	1.0227 (± 0.00714)	1.0227 (± 0.00655)	1.0223 (± 0.00766)
WD, n=9, 4, 1, 2, 3, 7	1.0206 (± 0.00532)	1.0228 (± 0.00772)	1.038 (± 0)	1.0175 (± 0.01768)

Notes:

[109] - ITT Population. Only those participants available at the specified time points were analyzed.

[110] - ITT Population. Only those participants available at the specified time points were analyzed.

[111] - ITT Population. Only those participants available at the specified time points were analyzed.

[112] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94 ^[113]	97 ^[114]		
Units: ratio				
arithmetic mean (standard deviation)				
BL, n=102, 101, 98, 99, 94, 97	1.0225 (± 0.00759)	1.0245 (± 0.00679)		
W8, n=63, 85, 84, 82, 82, 82	1.021 (± 0.00884)	1.0255 (± 0.00726)		
WD, n=9, 4, 1, 2, 3, 7	1.0273 (± 0.00306)	1.0164 (± 0.00824)		

Notes:

[113] - ITT Population. Only those participants available at the specified time points were analyzed.

[114] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Urine pH at Baseline and Week 8/Early Withdrawal

End point title	Urine pH at Baseline and Week 8/Early Withdrawal
End point description:	
Urine samples were collected for the measurement of urine pH by dipstick method at Baseline and at Week 8/Early Withdrawal. The Baseline value was the measurement taken at screening (Visit 1). Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).	
End point type	Secondary
End point timeframe:	
Baseline and Week 8/Early Withdrawal	

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	102 ^[115]	104 ^[116]	96 ^[117]	99 ^[118]
Units: scores on a scale				
arithmetic mean (standard deviation)				
BL, n=102, 104, 96, 99, 94, 97	6.11 (± 0.507)	5.98 (± 0.367)	6.05 (± 0.455)	5.97 (± 0.383)
W8, n=62, 84, 82, 83, 82, 82	6 (± 0.458)	6.13 (± 0.518)	6.1 (± 0.451)	5.99 (± 0.397)
WD, n=9, 4, 1, 2, 3, 7	6.11 (± 0.601)	6.13 (± 0.25)	6 (± 0)	6 (± 0)

Notes:

[115] - ITT Population. Only those participants available at the specified time points were analyzed.

[116] - ITT Population. Only those participants available at the specified time points were analyzed.

[117] - ITT Population. Only those participants available at the specified time points were analyzed.

[118] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94 ^[119]	97 ^[120]		
Units: scores on a scale				
arithmetic mean (standard deviation)				
BL, n=102, 104, 96, 99, 94, 97	6.01 (± 0.37)	6.04 (± 0.393)		
W8, n=62, 84, 82, 83, 82, 82	6 (± 0.437)	6.01 (± 0.368)		
WD, n=9, 4, 1, 2, 3, 7	5.67 (± 0.289)	5.93 (± 0.345)		

Notes:

[119] - ITT Population. Only those participants available at the specified time points were analyzed.

[120] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: 24-hour urinary cortisol excretion at Baseline and Week 8

End point title	24-hour urinary cortisol excretion at Baseline and Week 8
-----------------	---

End point description:

A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion at the following scheduled time points: within 7 days prior to Study Visit 3 (Baseline; Week 0) and Study Visit 8 (Week 8). The Baseline value for 24-hour urinary cortisol was taken from Visit 3. Urine Cortisol (UC) Population: all participants whose urine samples did not have confounding factors that could affect the interpretation of results.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56 ^[121]	69 ^[122]	75 ^[123]	75 ^[124]
Units: Nanomole per 24 hours (nmol/24hr)				
median (full range (min-max))				
Baseline	68.45 (12.9 to 261.2)	56.8 (6.8 to 385.4)	65.9 (9.6 to 463.5)	64.5 (20.1 to 311)
Week 8	64.7 (7.6 to 200)	60.8 (13.9 to 262.1)	53 (9.2 to 371.5)	56 (5.4 to 340)

Notes:

[121] - UC Population

[122] - UC Population

[123] - UC Population

[124] - UC Population

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72 ^[125]	70 ^[126]		
Units: Nanomole per 24 hours (nmol/24hr)				
median (full range (min-max))				
Baseline	73.4 (12.5 to 221.7)	75.69 (17.9 to 384.8)		
Week 8	62 (7.7 to 294.3)	58.39 (8 to 338.5)		

Notes:

[125] - UC Population

[126] - UC Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Week 8

End point title	Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Week 8
End point description:	Change from Baseline was calculated as the Week 8 value minus the Baseline value.
End point type	Secondary
End point timeframe:	Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[127]	105 ^[128]	101 ^[129]	103 ^[130]
Units: Millimeters of mercury (mmHg)				
arithmetic mean (standard deviation)				
SBP	0.8 (± 9.83)	0.3 (± 12.93)	-0.2 (± 12.06)	0.9 (± 11.51)

DBP	2.1 (\pm 6.96)	0.6 (\pm 9.19)	-0.3 (\pm 9.18)	0 (\pm 9.37)
-----	-------------------	-------------------	--------------------	-----------------

Notes:

[127] - ITT Population. Only those participants available at the specified time points were analyzed.

[128] - ITT Population. Only those participants available at the specified time points were analyzed.

[129] - ITT Population. Only those participants available at the specified time points were analyzed.

[130] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[131]	100 ^[132]		
Units: Millimeters of mercury (mmHg)				
arithmetic mean (standard deviation)				
SBP	0.9 (\pm 10.55)	1.1 (\pm 11.49)		
DBP	-0.2 (\pm 8.05)	1 (\pm 7.9)		

Notes:

[131] - ITT Population. Only those participants available at the specified time points were analyzed.

[132] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in heart rate at Week 8

End point title	Change from Baseline in heart rate at Week 8
End point description:	Change from Baseline was calculated as the Week 8 value minus the Baseline value.
End point type	Secondary
End point timeframe:	Baseline and Week 8

End point values	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD	GW685698X 300 µg OD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107 ^[133]	105 ^[134]	101 ^[135]	103 ^[136]
Units: Beats per minute				
arithmetic mean (standard deviation)	0.8 (\pm 10.12)	0.5 (\pm 7.65)	-0.4 (\pm 8.9)	1.5 (\pm 10.92)

Notes:

[133] - ITT Population. Only those participants available at the specified time points were analyzed.

[134] - ITT Population. Only those participants available at the specified time points were analyzed.

[135] - ITT Population. Only those participants available at the specified time points were analyzed.

[136] - ITT Population. Only those participants available at the specified time points were analyzed.

End point values	GW685698X 400 µg OD	FP 250 µg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99 ^[137]	100 ^[138]		
Units: Beats per minute				
arithmetic mean (standard deviation)	0.5 (\pm 8.55)	-1.7 (\pm 9.68)		

Notes:

[137] - ITT Population. Only those participants available at the specified time points were analyzed.

[138] - ITT Population. Only those participants available at the specified time points were analyzed.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the the treatment period (up to Week 8).

Adverse event reporting additional description:

SAEs and non-serious AEs were reported for members of the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received at least one dose of trial medication during the treatment period.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	11
--------------------	----

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study.

Reporting group title	GW685698X 100 µg OD
-----------------------	---------------------

Reporting group description:

Participants received GW685698X 100 micrograms (µg) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Reporting group title	GW685698X 200 µg OD
-----------------------	---------------------

Reporting group description:

Participants received GW685698X 200 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Reporting group title	GW685698X 300 µg OD
-----------------------	---------------------

Reporting group description:

Participants received GW685698X 300 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Reporting group title	GW685698X 400 µg OD
-----------------------	---------------------

Reporting group description:

Participants received GW685698X 400 µg OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Reporting group title	FP 250 µg BID
-----------------------	---------------

Reporting group description:

Participants received fluticasone propionate (FP) 250 µg BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 8 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.

Serious adverse events	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 107 (0.00%)	0 / 105 (0.00%)	0 / 101 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	0 / 107 (0.00%)	0 / 105 (0.00%)	0 / 101 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 107 (0.00%)	0 / 105 (0.00%)	0 / 101 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	GW685698X 300 µg OD	GW685698X 400 µg OD	FP 250 µg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 103 (0.97%)	1 / 99 (1.01%)	0 / 100 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	1 / 103 (0.97%)	0 / 99 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 103 (0.00%)	1 / 99 (1.01%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 3 %

Non-serious adverse events	Placebo	GW685698X 100 µg OD	GW685698X 200 µg OD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 107 (15.89%)	29 / 105 (27.62%)	18 / 101 (17.82%)
Nervous system disorders			
Headache			
subjects affected / exposed	6 / 107 (5.61%)	9 / 105 (8.57%)	8 / 101 (7.92%)
occurrences (all)	11	14	8
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 107 (0.00%)	4 / 105 (3.81%)	1 / 101 (0.99%)
occurrences (all)	0	5	1
Abdominal pain upper			
subjects affected / exposed	0 / 107 (0.00%)	2 / 105 (1.90%)	1 / 101 (0.99%)
occurrences (all)	0	2	1
Toothache			
subjects affected / exposed	0 / 107 (0.00%)	1 / 105 (0.95%)	1 / 101 (0.99%)
occurrences (all)	0	1	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 107 (0.93%)	2 / 105 (1.90%)	0 / 101 (0.00%)
occurrences (all)	1	2	0
Dysphonia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 105 (0.95%)	0 / 101 (0.00%)
occurrences (all)	1	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 107 (0.00%)	2 / 105 (1.90%)	1 / 101 (0.99%)
occurrences (all)	0	2	1
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 107 (0.00%)	1 / 105 (0.95%)	1 / 101 (0.99%)
occurrences (all)	0	2	1
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	8 / 107 (7.48%)	9 / 105 (8.57%)	5 / 101 (4.95%)
occurrences (all)	9	9	5
Upper respiratory tract infection			

subjects affected / exposed	3 / 107 (2.80%)	2 / 105 (1.90%)	3 / 101 (2.97%)
occurrences (all)	3	2	4
Oral candidiasis			
subjects affected / exposed	0 / 107 (0.00%)	3 / 105 (2.86%)	1 / 101 (0.99%)
occurrences (all)	0	4	1
Sinusitis			
subjects affected / exposed	1 / 107 (0.93%)	2 / 105 (1.90%)	0 / 101 (0.00%)
occurrences (all)	1	3	0

Non-serious adverse events	GW685698X 300 µg OD	GW685698X 400 µg OD	FP 250 µg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	22 / 103 (21.36%)	20 / 99 (20.20%)	32 / 100 (32.00%)
Nervous system disorders			
Headache			
subjects affected / exposed	8 / 103 (7.77%)	9 / 99 (9.09%)	8 / 100 (8.00%)
occurrences (all)	9	13	10
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 103 (0.97%)	1 / 99 (1.01%)	1 / 100 (1.00%)
occurrences (all)	1	1	1
Abdominal pain upper			
subjects affected / exposed	1 / 103 (0.97%)	3 / 99 (3.03%)	0 / 100 (0.00%)
occurrences (all)	1	7	0
Toothache			
subjects affected / exposed	0 / 103 (0.00%)	0 / 99 (0.00%)	3 / 100 (3.00%)
occurrences (all)	0	0	4
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 103 (1.94%)	4 / 99 (4.04%)	2 / 100 (2.00%)
occurrences (all)	2	5	2
Dysphonia			
subjects affected / exposed	2 / 103 (1.94%)	2 / 99 (2.02%)	4 / 100 (4.00%)
occurrences (all)	2	2	4
Oropharyngeal pain			
subjects affected / exposed	1 / 103 (0.97%)	3 / 99 (3.03%)	3 / 100 (3.00%)
occurrences (all)	1	5	3

Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	3 / 103 (2.91%)	3 / 99 (3.03%)	2 / 100 (2.00%)
occurrences (all)	3	7	2
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	7 / 103 (6.80%)	4 / 99 (4.04%)	7 / 100 (7.00%)
occurrences (all)	7	4	7
Upper respiratory tract infection			
subjects affected / exposed	1 / 103 (0.97%)	0 / 99 (0.00%)	6 / 100 (6.00%)
occurrences (all)	1	0	6
Oral candidiasis			
subjects affected / exposed	3 / 103 (2.91%)	3 / 99 (3.03%)	3 / 100 (3.00%)
occurrences (all)	3	3	4
Sinusitis			
subjects affected / exposed	0 / 103 (0.00%)	1 / 99 (1.01%)	3 / 100 (3.00%)
occurrences (all)	0	1	3

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
24 October 2007	<ul style="list-style-type: none">• Amend once daily GW685698X administration from morning to evening and to amend timing of measures that were impacted by this change• Amend inclusion criterion % predicted normal FEV1 range to account for evening measures
12 December 2007	<ul style="list-style-type: none">• Amend anti-asthma therapy inclusion criteria. Subjects must have been using an inhaled corticosteroid for at least 8 weeks prior to Visit 1 and maintained on a stable dose of inhaled corticosteroids for four weeks prior to Visit 1 at specified doses
21 March 2008	<ul style="list-style-type: none">• Adjust the FEV1 entry criteria depending on the time of day the screening period was conducted. A best FEV1 of 40%-85% of the predicted normal value during the Visit 1 screening period if the Visit occurred between 5:00 AM and 12:00 Noon or a best FEV1 of 40%-90% of the predicted normal value during the Visit 1 screening period if the Visit occurred between 5:00 PM and 11:00 PM.• Allow subjects to re-screen for Visit 1 if they failed to meet lung function criteria.• Clarify the exclusion of subjects with upper and lower respiratory tract infections at Visit 1 and Visit 3. Subjects were to be excluded if they had culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that was not resolved within 4 weeks of Visit 1 and that led to a change in asthma management, or in the opinion of the Investigator was expected to affect the subjects asthma status or the subject's ability to participate in the study.• Allow the use of long acting anti-histamines.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported